New investment to improve lung cancer outcomes in Yorkshire
Lung cancer is the most common cancer in the region.
Yorkshire Cancer Research has revealed plans to invest £6.5m in new initiatives that will improve lung cancer outcomes and increase early diagnosis in Yorkshire.
Lung cancer is the most common cancer in the region, with around 4,500 people diagnosed with the disease every year.
15 of 21 CCGs in Yorkshire had incidence rates higher than the national average in 20132. This differs from the national picture, where lung cancer is the third most common behind breast cancer and prostate cancer.
Around 67% of lung cancer patients are diagnosed at a late stage in Yorkshire, when the tumour may have grown or spread to other tissues or organs.
The investment will mark the first stage of the charity’s new strategy to ensure 2,000 more people in the region survive cancer every year by 2025. Successful projects will be announced in January 2017.
Charles Rowett, Chief Executive Officer at Yorkshire Cancer Research, said:
“We are delighted to be able to announce yet another significant investment in improving the diagnosis, treatment and care of people living in our region. This is only possible thanks to the continued support of people living in Yorkshire.
“Together, we can start having a real impact on cancer outcomes by finding practical solutions to our region’s problems and by working in the heart of our communities.”